Actuate Therapeutics (ACTU) Competitors $9.03 +0.20 (+2.27%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$9.03 0.00 (0.00%) As of 01/31/2025 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends ACTU vs. ORIC, QURE, CRMD, AVDL, CRON, SANA, SEPN, DNA, LENZ, and PLRXShould you be buying Actuate Therapeutics stock or one of its competitors? The main competitors of Actuate Therapeutics include ORIC Pharmaceuticals (ORIC), uniQure (QURE), CorMedix (CRMD), Avadel Pharmaceuticals (AVDL), Cronos Group (CRON), Sana Biotechnology (SANA), Septerna (SEPN), Ginkgo Bioworks (DNA), LENZ Therapeutics (LENZ), and Pliant Therapeutics (PLRX). These companies are all part of the "pharmaceutical products" industry. Actuate Therapeutics vs. ORIC Pharmaceuticals uniQure CorMedix Avadel Pharmaceuticals Cronos Group Sana Biotechnology Septerna Ginkgo Bioworks LENZ Therapeutics Pliant Therapeutics Actuate Therapeutics (NASDAQ:ACTU) and ORIC Pharmaceuticals (NASDAQ:ORIC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, community ranking, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings. Do analysts recommend ACTU or ORIC? ORIC Pharmaceuticals has a consensus price target of $18.29, indicating a potential upside of 75.49%. Given ORIC Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe ORIC Pharmaceuticals is more favorable than Actuate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actuate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00ORIC Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ACTU or ORIC more profitable? Actuate Therapeutics' return on equity of 0.00% beat ORIC Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Actuate TherapeuticsN/A N/A N/A ORIC Pharmaceuticals N/A -42.47%-38.86% Which has preferable earnings and valuation, ACTU or ORIC? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioActuate TherapeuticsN/AN/A-$24.75MN/AN/AORIC PharmaceuticalsN/AN/A-$100.70M-$1.80-5.79 Does the media favor ACTU or ORIC? In the previous week, Actuate Therapeutics had 1 more articles in the media than ORIC Pharmaceuticals. MarketBeat recorded 3 mentions for Actuate Therapeutics and 2 mentions for ORIC Pharmaceuticals. Actuate Therapeutics' average media sentiment score of 0.88 beat ORIC Pharmaceuticals' score of 0.44 indicating that Actuate Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Actuate Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ORIC Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders believe in ACTU or ORIC? 95.1% of ORIC Pharmaceuticals shares are owned by institutional investors. 5.6% of ORIC Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community believe in ACTU or ORIC? ORIC Pharmaceuticals received 65 more outperform votes than Actuate Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformActuate TherapeuticsN/AN/AORIC PharmaceuticalsOutperform Votes6573.03% Underperform Votes2426.97% SummaryORIC Pharmaceuticals beats Actuate Therapeutics on 6 of the 11 factors compared between the two stocks. Get Actuate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACTU and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACTU vs. The Competition Export to ExcelMetricActuate TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$171.68M$6.86B$5.57B$9.10BDividend YieldN/A2.90%5.32%3.99%P/E RatioN/A5.1864.0314.71Price / SalesN/A303.531,257.1080.89Price / CashN/A73.5045.9637.70Price / BookN/A5.275.124.70Net Income-$24.75M$136.98M$111.33M$224.47M7 Day Performance-10.68%-0.74%2.32%-0.18%1 Month Performance13.44%-2.02%1.57%-0.46%1 Year PerformanceN/A8.75%25.00%20.69% Actuate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACTUActuate TherapeuticsN/A$9.03+2.3%N/AN/A$171.68MN/A0.0010News CoverageORICORIC Pharmaceuticals4.0082 of 5 stars$10.86+5.1%$18.29+68.5%-9.5%$767.45MN/A-6.0480Positive NewsQUREuniQure3.4438 of 5 stars$15.58-0.5%$40.00+156.7%+183.1%$750.45M$15.84M-3.10500Analyst RevisionNews CoverageCRMDCorMedix2.2931 of 5 stars$12.29-1.0%$15.67+27.5%+237.8%$744.79M$60,000.00-15.1530Gap DownAVDLAvadel Pharmaceuticals3.3 of 5 stars$7.51-4.4%$21.00+179.7%-46.3%$718.85M$27.96M-9.4470Analyst RevisionCRONCronos Group1.5385 of 5 stars$1.88-1.3%$3.00+60.0%-12.0%$716.81M$87.24M-14.42450Short Interest ↓SANASana Biotechnology3.0098 of 5 stars$3.21-5.2%$14.25+344.6%-44.8%$711.11MN/A-2.28380Short Interest ↑SEPNSepternaN/A$15.94-13.8%$43.67+174.0%N/A$709.96MN/A0.00N/ADNAGinkgo Bioworks0.636 of 5 stars$11.71-8.7%$4.58-60.9%N/A$674.75M$217.11M-0.901,218News CoverageGap DownLENZLENZ Therapeutics1.9318 of 5 stars$24.38-0.7%$35.40+45.2%N/A$667.15MN/A0.00110Upcoming EarningsAnalyst RevisionNews CoveragePLRXPliant Therapeutics3.9809 of 5 stars$10.91-0.1%$40.50+271.1%-41.6%$662.41M$1.58M-3.2690 Related Companies and Tools Related Companies ORIC Competitors QURE Competitors CRMD Competitors AVDL Competitors CRON Competitors SANA Competitors SEPN Competitors DNA Competitors LENZ Competitors PLRX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ACTU) was last updated on 2/2/2025 by MarketBeat.com Staff From Our PartnersStunning Trump Manhattan Project Now UnderwayJust as I predicted, President Trump announced his #1 move during his first 100 days... His allies are call...Banyan Hill Publishing | SponsoredTrump’s New AI Move Could Trigger Massive Melt UPIn his first week in office, President Trump already revoked President Biden's disastrous AI executive order.....InvestorPlace | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredStart Collecting Your $4,243 Monthly Paycheck Next WeekI've just released updated details on a new system for collecting steady dividend income each and every month....Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actuate Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Actuate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
